NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis
USA - NASDAQ:NKTR - US6402683063 - Common Stock
59.58 USD
+2.9 (+5.12%)
59.95 USD
+0.37 (+0.62%)
Taking everything into account, NKTR scores 3 out of 10 in our fundamental rating. NKTR was compared to 192 industry peers in the Pharmaceuticals industry. While NKTR has a great health rating, there are worries on its profitability. NKTR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
NKTR had negative earnings in the past year.
NKTR had a negative operating cash flow in the past year.
NKTR had negative earnings in each of the past 5 years.
In the past 5 years NKTR always reported negative operating cash flow.
1.2 Ratios
NKTR has a Return On Assets (-40.07%) which is comparable to the rest of the industry.
With a Return On Equity value of -141.90%, NKTR is not doing good in the industry: 67.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.07% | ||
| ROE | -141.9% | ||
| ROIC | N/A |
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 87.26%, NKTR belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
NKTR's Gross Margin has declined in the last couple of years.
NKTR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
2. Health
2.1 Basic Checks
NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
NKTR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, NKTR has more shares outstanding
There is no outstanding debt for NKTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -14.74, we must say that NKTR is in the distress zone and has some risk of bankruptcy.
NKTR has a worse Altman-Z score (-14.74) than 78.13% of its industry peers.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.74 |
ROIC/WACCN/A
WACC8.84%
2.3 Liquidity
A Current Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
NKTR has a Current ratio of 4.24. This is in the better half of the industry: NKTR outperforms 63.54% of its industry peers.
NKTR has a Quick Ratio of 4.24. This indicates that NKTR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NKTR (4.24) is better than 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.24 | ||
| Quick Ratio | 4.24 |
3. Growth
3.1 Past
NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.13%, which is quite good.
NKTR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.79%.
The Revenue has been decreasing by -3.00% on average over the past years.
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
Revenue 1Y (TTM)-32.79%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.13%
3.2 Future
Based on estimates for the next years, NKTR will show a decrease in Earnings Per Share. The EPS will decrease by -0.28% on average per year.
Based on estimates for the next years, NKTR will show a small growth in Revenue. The Revenue will grow by 3.64% on average per year.
EPS Next Y-0.44%
EPS Next 2Y-0.16%
EPS Next 3Y-5.19%
EPS Next 5Y-0.28%
Revenue Next Year-57.38%
Revenue Next 2Y-36.02%
Revenue Next 3Y-30.01%
Revenue Next 5Y3.64%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Also next year NKTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NKTR's earnings are expected to decrease with -5.19% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.16%
EPS Next 3Y-5.19%
5. Dividend
5.1 Amount
NKTR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
59.58
+2.9 (+5.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.3%
Inst Owner Change63.6%
Ins Owners0.71%
Ins Owner Change-3.12%
Market Cap1.13B
Revenue(TTM)62.60M
Net Income(TTM)-120.74M
Analysts81.43
Price Target95.04 (59.52%)
Short Float %9.17%
Short Ratio1.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.21%
Min EPS beat(2)4.71%
Max EPS beat(2)31.71%
EPS beat(4)3
Avg EPS beat(4)-0.01%
Min EPS beat(4)-43.22%
Max EPS beat(4)31.71%
EPS beat(8)5
Avg EPS beat(8)-0.46%
EPS beat(12)7
Avg EPS beat(12)-0.71%
EPS beat(16)11
Avg EPS beat(16)4.27%
Revenue beat(2)2
Avg Revenue beat(2)8.01%
Min Revenue beat(2)0.98%
Max Revenue beat(2)15.04%
Revenue beat(4)2
Avg Revenue beat(4)-5.38%
Min Revenue beat(4)-33.31%
Max Revenue beat(4)15.04%
Revenue beat(8)6
Avg Revenue beat(8)13.39%
Revenue beat(12)8
Avg Revenue beat(12)9.53%
Revenue beat(16)9
Avg Revenue beat(16)6.67%
PT rev (1m)-10.15%
PT rev (3m)-1.74%
EPS NQ rev (1m)5.06%
EPS NQ rev (3m)3.73%
EPS NY rev (1m)3.18%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)-5.09%
Revenue NQ rev (3m)-4.3%
Revenue NY rev (1m)-0.75%
Revenue NY rev (3m)-2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 13.32 | ||
| P/tB | 13.32 | ||
| EV/EBITDA | N/A |
EPS(TTM)-10.82
EYN/A
EPS(NY)-11.74
Fwd EYN/A
FCF(TTM)-10.01
FCFYN/A
OCF(TTM)-9.98
OCFYN/A
SpS3.29
BVpS4.47
TBVpS4.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.07% | ||
| ROE | -141.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.26% | ||
| FCFM | N/A |
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
F-Score4
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.4% | ||
| Cap/Sales | 0.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.24 | ||
| Quick Ratio | 4.24 | ||
| Altman-Z | -14.74 |
F-Score4
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)29.45%
Cap/Depr(5y)49.23%
Cap/Sales(3y)2.88%
Cap/Sales(5y)5.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
EPS Next Y-0.44%
EPS Next 2Y-0.16%
EPS Next 3Y-5.19%
EPS Next 5Y-0.28%
Revenue 1Y (TTM)-32.79%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.13%
Revenue Next Year-57.38%
Revenue Next 2Y-36.02%
Revenue Next 3Y-30.01%
Revenue Next 5Y3.64%
EBIT growth 1Y-0.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.83%
EBIT Next 3Y-10.5%
EBIT Next 5YN/A
FCF growth 1Y6.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.67%
OCF growth 3YN/A
OCF growth 5YN/A
NEKTAR THERAPEUTICS / NKTR FAQ
What is the fundamental rating for NKTR stock?
ChartMill assigns a fundamental rating of 3 / 10 to NKTR.
Can you provide the valuation status for NEKTAR THERAPEUTICS?
ChartMill assigns a valuation rating of 0 / 10 to NEKTAR THERAPEUTICS (NKTR). This can be considered as Overvalued.
What is the profitability of NKTR stock?
NEKTAR THERAPEUTICS (NKTR) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for NKTR stock?
The Earnings per Share (EPS) of NEKTAR THERAPEUTICS (NKTR) is expected to decline by -0.44% in the next year.